AGA: 3 updates on FMT

The American Gastroenterological Association will host the 2014 James W. Freston Conference in Chicago, which will feature new research on fecal microbiota transplantation. Here are three updates on FMT to know.

•    FMT for more than just C. difficile. FMT has been demonstrated as a safe, effective treatment for patients with refractory CDI. Studies presented at the upcoming conference suggest that FMT has strong potential as an irritable bowel syndrome and inflammatory bowel disease treatment.
•    FMT in oral form. FMT has a number of liabilities, such as complexity of donor management and potential to transmit pathogens. Research at this meeting will show that orally delivery microbes, SER-109, developed by Seres Health proved to be effective and safe in a study population.
•    FMT acceptance. FMT is associated with a significant stigma – the "yuck factor." Research presented at the conference examines the factors that lead to acceptance of the procedure. For example, patients with children are more likely to accept the procedure.

More articles on gastroenterology:
FDA approves colonoscopy alternative Cologuard: 4 things to know
Best ideas for entrepreneurial gastroenterologists: Public presence, ASC ownership & more
Randomized trial of FMT for IBD yields mixed results

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers